The franchise drug for autoimmune disorders such as dermatitis could face a challenger: A candidate from Apogee Therapeutics.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) ranks among the 30 stocks expected to beat the market by 20 percentage points this ...

In a June 24, 2025, podcast, Goldman Sachs’ Christian Mueller-Glissmann and Alexandra Wilson-Elizondo examined the dynamics ...

RBC Capital maintained its Outperform rating on Xenon Pharmaceuticals Inc. (NASDAQ:XENE) and increased its price target from $55 to $57 on June 13.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the 13 Stocks Under $5 With High Upside Potential. On May 29, Leerink ...

In the assessment of 12-month price targets, analysts unveil insights for Axsome Therapeutics, presenting an average target of $179.18, a high estimate of $200.00, and a low estimate of $150.00.

Neurological disorders are disorders that affect the central nervous system or the peripheral nervous systems and can impair the brain, spinal cord, peripheral nerve or neuromuscular function ...

Health P.E.I. says reduced staffing will mean oncology patients usually treated at Prince County Hospital will now have to ...